Press
EpiVax Awarded a Grant for Hemophilia Therapy
Posted on July 25, 2007 by epivax3PROVIDENCE BUSINESS NEWS By David Ortiz A Providence-based biotechnology pharmaceutical firm that genetically engineers new vaccines has received a $528,313 grant to begin developing a novel treatment for hemophilia. EpiVax Inc. will use the grant, from the National Institutes of Health, to reengineer Factor VIII, a clotting agent in the blood that is deficient in hemophiliacs. ...Read moreEpiVax funded to advance research on a new, improved “Botox”
Posted on March 25, 2007 by epivax3February 26, 2007 (Providence, RI)—- EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as ...Read moreEpiVax wins SBIR Phase I grant totaling $993,771 to Develop Smallpox Vaccine
Posted on June 15, 2005 by epivax3Providence, RI, December 17, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the ...Read moreEpiVax Is Awarded H. Pylori SBIR Grant by National Institutes of Health
Posted on June 1, 2005 by epivax3PROVIDENCE, RI — 04/27/2005 — EpiVax, Inc., a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities and pharmaceutical companies, today announced that it was awarded a $600,000 Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The grant award ...Read moreEpiVax moves to new facility at 146 Clifford Street including office and laboratory space
Posted on November 25, 2004 by epivax3EpiVax moves to new facility at 146 Clifford Street including office and laboratory spaceRead moreEpiVax wins SBIR Phase I grant totaling $859,773 to Develop Tularemia Vaccine
Posted on September 1, 2004 by epivax3Providence, RI, September 8, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National ...Read moreEpiVax signs Master Services Agreement with Amgen
Posted on July 25, 2004 by epivax3EpiVax signs Master Services Agreement with AmgenRead moreEpiVax renews technology license with Brown University
Posted on August 25, 2003 by epivax3EpiVax renews technology license with Brown UniversityRead moreEpiVax receives $150,000 in phase II funding from Slater Center for Bio-Technology
Posted on March 25, 2003 by epivax3EpiVax receives $150,000 in phase II funding from Slater Center for Bio-TechnologyRead moreEpiVax signs Master Services Agreement with Brown University
Posted on March 20, 2003 by epivax3EpiVax signs Master Services Agreement with Brown UniversityRead moreEpiVax signs Laboratory Services Agreement with Eli Lilly
Posted on March 25, 2002 by epivax3EpiVax signs Laboratory Services Agreement with Eli LillyRead moreAwarded SBIR Phase I grant for West Nile Virus diagnostic project
Posted on September 25, 2001 by epivax3Awarded SBIR Phase I grant for West Nile Virus diagnostic projectRead moreAwarded SBIR Phase I grant for Human Papiloma Virus vaccine project
Posted on September 20, 2001 by epivax3Awarded SBIR Phase I grant for Human Papiloma Virus vaccine projectRead moreSigned strategic cooperation and co-marketing agreement with Beckman Coulter Immunomics
Posted on June 25, 2001 by epivax3Signed strategic cooperation and co-marketing agreement with Beckman Coulter ImmunomicsRead moreAnne De Groot named Core Scientist by Sequella Global TB Foundation and awarded 3 year $900,000 TB vaccine development grant
Posted on April 25, 2000 by epivax3Anne De Groot named Core Scientist by Sequella Global TB Foundation and awarded 3 year $900,000 TB vaccine development grantRead more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.